Form 4: Q32 Bio Inc. Director Acquires Stock Options
SEC Form 4 Filing
Director Sven Ante Lundberg acquired stock options in Q32 Bio Inc. on September 25, 2024.
Summary
- Sven Ante Lundberg, a director of Q32 Bio Inc., reported a transaction involving derivative securities.
- On September 25, 2024, Lundberg acquired stock options representing the right to buy 1,316 shares of Q32 Bio Inc. common stock at an exercise price of $44.40.
- The options vest in three equal quarterly installments on June 30, 2024, September 30, 2024, and December 31, 2024.
- Following the transaction, Lundberg directly owns derivative securities representing 1,316 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors.
Stakeholder Impact
- The transaction could signal confidence in the company's future prospects to shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/30/2024 | First vesting date for the stock options. |
| 09/25/2024 | Date of the stock option acquisition. |
| 09/30/2024 | Second vesting date for the stock options. |
| 12/31/2024 | Third vesting date for the stock options. |
| 09/24/2034 | Expiration date of the stock options. |
| 09/27/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.